Short LLY at 910 Target 780. (Stop on a daily close above 912)Id like to take a swing short on LLY due to its failed breakout and mini head and shoulders pattern. Enter at 910 with a stop on a daily close above 912. Target is 870.
Thanks
Kavi
LLYC trade ideas
ELI LILLY: This consolidation is a buy opportunity.Eli Lilly is neutral on its 1D technical outlook (RSI = 52.880, MACD = 1.910, ADX = 25.797) as well as on 1W as for the past 7 weeks it has turned sideways. This consolidation is taking place half-way through the new bullish wave of the Channel Up that started in early 2023. As you see it is supported by the 1W MA50 and every bullish wave in the beginning was almost at +50% but the latest one was +35%. Consequently we expect a minimum of +46.22% from the bottom and that's what we're aiming for (TP = 1,095).
See how our prior idea has worked out:
## If you like our free content follow our profile to get more daily ideas. ##
## Comments and likes are greatly appreciated. ##
ELI LILLY Always a solid buy below its 1D MA50.Eli Lilly (LLY) broke on Friday below its 1D MA50 (blue trend-line) for the first time since August 09. As the stock trades within a long-term Channel Up since the March 01 2023 bottom, every time the price was below the 1D MA50, it didn't stay for long, thus providing the most effective buy entry.
Even though it could dip some more as with July's decline (only such case though out of 6 corrections), as long as the 1D MA200 (orange trend-line) holds, we expect the Channel Up to be extended.
The initial Higher Highs were closer to the 1.5 Fibonacci Channel extension, the last one however was exactly on the 1.0 Fib. As a result, we will take a more conservative Target on that trend-line, thus turning bullish now and aiming at $1100 by the end of the year.
-------------------------------------------------------------------------------
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. **
-------------------------------------------------------------------------------
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇
Positive Signs for Eli Lilly : Upward Movement at a Low PointThe LLY price seems to have reached a bottom and is now showing signs of upward movement. This trend could indicate a potential reversal, making it an attractive opportunity for investment. If the upward momentum continues, it may suggest increasing confidence in the stock's future performance.
However, it’s essential to consider other factors such as market conditions, company fundamentals, and your own investment strategy before making a decision.
Consolidation brokenPrice dropped below consolidation channel
Probably will continue to drop because a gap is waiting to be filled
I think price will touch sma200 again and then a strong up move can happen
LLYLet's see if Eli Lilly can win the race - is it a bull flag finish to the upside or red candles in the future of this name? NYSE:LLY
LLY: Entry Volume, Target, StopEntry: > 972.53
Volume: > 3.184M
Target: 1,117.98 area (this is an area, no guarantees, you should be selling on the way up)
Stop: Depending on your risk tolerance; Based on an entry of 972.53, 899.93 gets you 2/1 Reward to Risk Ratio.
This LONG swing trade idea is not trade advice and is strictly based on my ideas and technical analysis. No due diligence or fundamental analysis was performed while evaluating this trade idea. Do not enter a trade based on my idea, do not follow anyone blindly, do your own analysis and due diligence. I am not a professional trader.
Testing the 900 after filling the gap As the last daily chart informatively dictating another shift in directional change. Will it test the 900 aggressively or bounce back up on solid monetary policy.
LLY: The Next Support Levels to Watch!On the daily chart, after a strong rally towards the resistance level at $966.10, LLY has experienced a sharp pullback. The stock failed to break through the key resistance and showed a strong rejection at that level, indicating a potential top signal. The bearish momentum is evident as the price is heading toward a possible retracement zone. The Fibonacci retracement levels show key levels to watch, with the 38.2% retracement near $880, and further possible retracements toward 50% at $849 and 61.8% at $825. The 21-day EMA is still trending upwards but is now being tested as the price begins to weaken. If lost, then the retracements will be our next targets.
On the weekly chart, a clear V-shape recovery is visible, which culminated in a significant rise back toward the $966 resistance area. However, the rejection at this level has formed a potential double top, which is often a bearish reversal signal. The price has now pulled back sharply, which aligns with the signals on the daily chart. If the price continues to decline, the $850 area around the 21-week EMA will be critical support levels to monitor, whichc coincides witth the 50% retracement level observed on the daily chart. If the price breaks below these levels, it could indicate a deeper correction is underway.
In conclusion, LLY appears to be in a corrective phase after failing to break through the key resistance at $966. For now, we should keep an eye on the key Fibonacci retracement levels and the 21-EMA for potential support during this pullback. A continued failure to hold these levels could lead to more downside pressure in the short term.
For more detailed technical analyses and insights like this, be sure to follow my account. Your support helps me continue providing valuable content to help you make informed trading decisions.
Remember, real trading is reactive, not predictive, so let's stay focused on the key points described above and only trade when there is confirmation.
“To anticipate the market is to gamble. To be patient and react only when the market gives the signal is to speculate.” — Jesse Lauriston Livermore
All the best,
Nathan.
1027 at the higher level of upper bollingerDaily analysis varies by sentiment and political news. The technicals, however, are close to a squeeze.
Eli Lilly's Zepbound: A Game-Changer for Obesity Treatment?In a groundbreaking move that could redefine the landscape of obesity treatment, Eli Lilly has slashed the price of its weight loss drug, Zepbound, by half. But is this simply a strategic business decision, or is it a beacon of hope for millions struggling with obesity? Join us as we delve into the implications of this bold move and explore the potential impact on the future of weight management.
Imagine a world where obesity is no longer a daunting, insurmountable challenge. A world where effective, affordable treatments are accessible to all who need them. Eli Lilly's recent announcement of a significant price reduction for Zepbound brings us closer to that reality.
By making this groundbreaking decision, Eli Lilly has not only demonstrated its commitment to patient access but has also sent a powerful message to the broader healthcare industry. This move has the potential to disrupt the status quo, challenging the outdated policies and practices that have hindered progress in obesity treatment.
As we explore the implications of Eli Lilly's decision, we must consider the broader context of the obesity epidemic. For decades, obesity has been stigmatized and overlooked as a serious medical condition. Many individuals struggling with weight loss have faced limited treatment options and significant financial burdens.
Eli Lilly's move to lower the price of Zepbound could be a game-changer in this regard. By making the drug more affordable, the company is empowering patients to take control of their health and pursue a healthier lifestyle. This could lead to a significant increase in the number of people seeking treatment for obesity, ultimately improving public health outcomes.
However, it is important to note that this is just one step in a larger journey. While Eli Lilly's decision is undoubtedly a positive development, more needs to be done to address the systemic issues that contribute to the obesity epidemic. Policymakers, healthcare providers, and communities must work together to create a supportive environment that promotes healthy eating, physical activity, and access to affordable, effective treatments.
In conclusion, Eli Lilly's announcement of a price reduction for Zepbound represents a significant milestone in the fight against obesity. By making this drug more accessible, the company is not only helping individuals achieve their weight loss goals but also challenging the broader healthcare system to prioritize obesity treatment.
WATCHLIST 8/25 PART 2AMEX:IWM - Russell 2000 Outshines S&P 500, Nasdaq 100 As Powell Eyes Rate Cuts. Looking to add calls as long as $220 holds for a move towards $225 and higher.
BMV:BRKB - another stock breaking all time highs on Friday. Stock is breaking out on charts. Calls above $455 for a move towards $470. Stock is strong on indicators.
NYSE:LLY - the company announced results showing “it Tirzepatide injections reduced the risk of progression to type 2 diabetes by 94% in adults with pre-diabetes and obesity.” looking for calls above $950 for a move towards MIL:1K and higher
NASDAQ:COIN - another Bitcoin related stock on watch as bitcoin moves higher. Calls added in group for swing. Next resistance at $216.6. More upside above that level.
NYSE:HD - Stock breaking recent highs at $376. Stock is a decent uptrend. Rate cut news should help. Calls above $377 for a move towards $385 and $400. Stock is strong on indicator level.
Golden cross to the top here we go 1000Position accurately, making this close to retracing but not enough room to run as we are close to the end, I would like to see that maximum at 1000+ before I see a reversal. Watching closely.
ELI LILLY Recovered all losses from its High! What's next?Eli Lilly and Company (LLY) posted a miraculous bullish reversal in the past 2 weeks, recovering yesterday all of the losses of the brutal correction since its July 15 All Time High. Having rebounded on its 1D MA200 (orange trend-line) while the 1D RSI touched the 30.00 oversold barrier for the first time since February 28 2023, we can claim that LLY's Channel Up now sets eyes for its next Higher High.
This pattern is best illustrated with the use of the Fibonacci Channel levels. After initially holding the 1.0 Fib as Resistance, the 'ceiling' is now the 1.5 Fib extension, basically has been since September 12 2023.
The interesting parameter of this pattern is that every approximately +35.00 to +40.00% rise, the price pulls back or turns sideways (red arc pattern) until it eventually hits the 1D MA50 (blue trend-line).
As the stock completes a +35% rise from the bottom, a little above the 1000 mark, we expect it to turn sideways at best. The target after that is $1200, exactly on the 1.0 Fibonacci level, which is still a modest one, considering that the ceiling is now the 1.5 Fib extension, as discussed above.
-------------------------------------------------------------------------------
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. **
-------------------------------------------------------------------------------
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇
#ELI LILLY $LLY back to ATH! What's next for LLY (Long term).Eli Lilly (LLY) stock jumped more than 3% to a record high on Tuesday after clinical trial results showed tirzepatide—the active ingredient in Lilly's injectable weight-loss drug Zepbound and diabetes treatment Mounjaro—lowered patients' risk of developing type 2 diabetes by 94%.
LLY is climbing back toward its record high of 966.10 reached on July 15.
The three-year study of patients with prediabetes and either obesity or overweight also found that those who received tirzepatide lost 22.9% of their body weight on average, compared with 2.1% for patients treated with a placebo.
Eli Lilly shares jumped to an all-time high on Tuesday, bringing their year-to-date return to more than 60%.
This is very bullish news for LLY. This is easily a 1k stock and a good long term investment if you want exposure to the Glucagon-like peptide-1 meds (GLP-1). LLY is number one in that field hands down.
Consensus around 100bn, current 950.
Research material for you:
Alzheimer's potential benefits.
Novo data (NVO), 2025.
upper 800s promising for another reversalThis stock moves a lot and is moving on the upside, but many indicators suggest this could be changing.
LLY: On The Brink Of CollapseEli Lilly is the one stock I've made the most returns on this year. With it's violent up and down swings, it's exactly what you look for as an options trader. As I've been observing LLY over the last few weeks, I decided to go back in time again to the origins of this monstrous parabolic move and share it with you all. If you look at the smaller time frames, you will see that LLY has filled it's gap target to the upside, but there are so many gaps to the downside. When the market does decide to fall hard, I believe LLY will fall the hardest. Is this not the perfect stock to fit the old adage, "THE BIGGER THEY ARE, THE HARDER THEY FALL?" Once LLY breaks below 747, the next targets are well below the current price. This means BIG returns for options traders. I don't see much more upside for this stock (if any), so the downside potential will play favorably.
PT1 747 PT2 609
Targets are 1 to 2 months.
LLY bullishLLY has bounced off 200 EMA
LLY has a daily candle closed above 50 MA
This confirms the technical bullish bias
and it should now break the previous high .
Positions should be taken now to ride the bullish wave
Stop loss is 708
LLY 1H Long Swing Aggressive trend tradeAggressive trend trade
- short impulse
+ biggest volume T1
+ biggest volume manipulation
Calculated affordable stop limit
1 to 2 R/R take profit after 1/2!!!
Daily context
"+ long impulse
+ 1/2 correction"
Monthly context
"+ long impulse
- neutral zone"
LLY @NYSE
Sell Stop 901.82 LMT 905.94, GTC
Sell Limit 913.63, GTC
Eli Lilly Shares Surge Over 9% After Strong Earnings ReportEli Lilly Shares Surge Over 9% After Strong Earnings Report
As the chart of Eli Lilly's (LLY) share price shows today, yesterday's trading closed at a level more than 9% higher than Wednesday's closing price. The main driver of this growth was a strong Q2 report:
→ Earnings per share: actual = $3.92, expected = $2.74;
→ Gross sales: actual = $11.3 billion, expected = $9.99 billion.
Market participants reacted positively not only to the fact that the American pharmaceutical company's actual results significantly exceeded forecasts but also to Eli Lilly's rising expectations for the second half of the year, driven by demand for its diabetes treatment Mounjaro and weight loss drug Zepbound.
Technical analysis of the Eli Lilly (LLY) stock chart shows that:
→ The price action is forming an upward channel in 2024 (shown in blue);
→ After a rebound, the median line of this channel was breached (as indicated by the arrow);
→ As could be expected, this line acted as resistance – as indicated by the high of yesterday's candlestick.
What is the forecast for Eli Lilly (LLY) shares?
Wall Street analysts surveyed by TipRanks remain positive – none of them recommend selling shares of the company, which has the largest market cap in the healthcare sector at over $800 billion. On average, they forecast that LLY shares will reach $955 within 12 months.
This suggests that the current upward channel may remain relevant. However, it’s possible that:
→ The lower boundary will continue to act as support;
→ The boundaries of the bullish gap formed at yesterday's opening may also provide support. A similar action can be seen on the chart – after a wide bullish gap (also formed following a strong report) on 30 April, LLY shares found support near the lower boundary of that gap around $740.
This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
Eli Lilly Surges 12% On Strong Earnings Beat and Q2 ReportsEli Lilly & Co. (NYSE: NYSE:LLY ) has once again captured the spotlight with its impressive second-quarter performance in 2024. The pharmaceutical giant’s stock surged by over 12% following the announcement of its quarterly earnings, driven largely by the soaring sales of its diabetes drug Mounjaro and weight loss injection Zepbound.
Blowing Past Expectations
Eli Lilly reported $11.3 billion in revenue and $2.97 billion in net profit for Q2, far exceeding Wall Street’s expectations. Analysts had anticipated $9.97 billion in revenue and $2.48 billion in profit, according to FactSet. The company also reported earnings per share (EPS) of $3.28, significantly higher than the $2.74 forecasted by analysts.
This remarkable performance marks a 36% increase in revenue and a staggering 68% increase in profit compared to the same period last year. In Q2 2023, Lilly had reported $8.31 billion in sales and $1.76 billion in profit.
The pharmaceutical giant’s strong earnings prompted a bullish revision of its full-year guidance. Eli Lilly raised its forecasted EPS for the year to between $16.10 and $16.60, up from its previous guidance of $13.50 to $14 per share. Additionally, the company now expects annual revenue to range between $45.4 billion and $46.6 billion, an increase of $3 billion at both ends of the range.
Mounjaro and Zepbound: The Driving Forces
The extraordinary demand for Lilly’s diabetes and weight loss drugs, Mounjaro and Zepbound, has been the primary catalyst for its Q2 success. Mounjaro, which generated $3.09 billion in revenue during the quarter, saw its sales more than triple from the same period last year. Zepbound, a relatively new entrant to the market, raked in $1.24 billion in sales, far surpassing the $922.2 million that analysts had projected.
The growth in Mounjaro and Zepbound’s sales comes amidst a broader surge in the weight loss drug market, which some analysts estimate could reach $130 billion by the end of the decade. Eli Lilly, along with Danish competitor Novo Nordisk, has established a near-duopoly in this space, though the field is rapidly attracting interest from other pharmaceutical giants and startups.
Navigating Supply Challenges
The extraordinary demand for Mounjaro and Zepbound has led to supply constraints, a challenge that Eli Lilly has been aggressively addressing. The company has invested heavily in expanding its manufacturing capabilities, including building six new plants and hiring thousands of workers. The recent easing of supply issues for both drugs in the U.S. is a testament to these efforts.
Eli Lilly’s CEO, David Ricks, expressed confidence in the company’s ability to meet the growing demand for its products. “We just see unbelievable demand, and we’re not even trying that hard to market this drug,” Ricks told CNBC. He added that the company’s supply chain improvements have been crucial in driving the quarter’s success.
Future Outlook: Beyond Weight Loss
Eli Lilly is not resting on its laurels. The company is actively working to expand its dominance in the weight loss drug market by developing new treatments and exploring additional uses for its existing drugs. Two promising candidates are in late-stage clinical trials: orfoglipron, an oral weight loss pill, and retatrutide, a hormone-mimicking injection. Results for orfoglipron are expected next year, while retatrutide’s results are anticipated in 2026.
Furthermore, Lilly is exploring new indications for its drugs, such as using Zepbound to treat sleep apnea. If successful, this could further bolster Lilly’s market position and open new revenue streams.
Market Reaction and Investor Confidence
Eli Lilly’s robust earnings report and optimistic outlook have led to a surge in investor confidence. The company’s shares jumped 10% during premarket trading following the earnings announcement, and they have continued to climb, reflecting the market’s positive reception.
With a market capitalization of over $730 billion, Eli Lilly (NYSE: NYSE:LLY ) is now the largest pharmaceutical company in the U.S. The company’s stock has risen more than 30% this year, building on a nearly 60% increase in 2023. This growth underscores investor confidence in the long-term potential of Lilly’s drug pipeline and its ability to navigate the challenges of a highly competitive market.
Conclusion
Eli Lilly’s Q2 2024 earnings report highlights the company’s strong market position and its ability to capitalize on the booming demand for diabetes and weight loss treatments. With a robust pipeline, aggressive expansion plans, and a clear focus on innovation, Eli Lilly is well-positioned to maintain its leadership in the pharmaceutical industry for years to come. As the company continues to develop new drugs and expand its market reach, investors and industry observers alike will be watching closely to see how Lilly navigates the evolving landscape.
Could rock the earning world!A few key points to note are that the support has played a significant resistance since the YTD crossover of higher EMA still shows signs of bear territory, but I also see a major component by playing out above the shade and may consolidate, but if the price action is anything to judge this by then we could be in for a volatile run until I see some sort of reversal in effect. Definitely one to watch.
